Opsona Therapeutics Limited

The Provost, Fellows, Foundation Scholars, and the Other Members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin

Team Aer Lingus

Brian Keogh

Luke O'Neill

Christopher Phillip Locher

Mark Heffernan

Peter McGuirk

Peter Mcguirk

Fatih Arslan

Brendan Farrell

John Byrne

Barry Noel Harrington

Mathias Block

Padraig Furlong

Tatyana Sergeevna Lysakova

Andrew Graham Bowie

Gerard Pasterkamp

Dominique De Kleijn

Christopher Locher

The present invention provides compounds and methods for the treatment and prophylaxis of renal disease and inflammation. In particular the invention provides methods for the treatment of kidney disease and failure through the administration of compounds which function as inhibitors of TLR2 function and expression.

Treatment of renal disease

The present invention provides compounds and methods for the treatment and prophylaxis of ischemia reperfusion injury. In particular the invention provides compounds which function to suppress Toll-like Receptor 2 biological function or expression.

Composition and method for treatment of reperfusion injury and tissue damage

A peptide for inhibiting Toll-like receptor 4 (TLR4) signalling comprising the amino acid sequence of SEQ ID NO. 4, SEQ ID NO 55, SEQ ID NO 68, SEQ ID NO. 69, SEQ ID NO 70, SEQ ID NO 71, SEQ ID NO 72, SEQ ID NO 79, SEQ ID NO 82, SEQ ID NO 85, SEQ ID NO 88, SEQ ID NO 91, SEQ ID NO 94, SEQ ID NO 97, SEQ ID NO 100, SEQ ID NO 103, SEQ ID NO 106, SEQ ID NO 109, SEQ ID NO 112, or SEQ ID NO 115. The peptide may comprise a delivery sequence such as a cationic peptide.

Vaccinia virus protein A46 peptide and use thereof

The present invention provides compositions and methods for the treatment of autoimmune diseases, in particular rheumatoid arthritis. Compounds which function as antagonists of Toll-like Receptor 2 are shown to suppress the immune response which result in the onset and progression of autoimmune disease. In particular monoclonal antibodies which have a binding specificity to Toll-like receptor 2 are disclosed for use in methods for the treatment and/or prophylaxis of autoimmune disease.

Method for the treatment of rheumatoid arthritis using a TLR2 antagonistic antibody

A halogenated hydrocarbon recycling machine M1 comprising a cylinder-emptying apparatus including means for transferring a vapour mixture from a cylinder 10 to a fluid storage reservoir R1, a cylinder-filling apparatus including means for filling the cylinder 10.sup.1 from the reservoir R1 and a fluid separating apparatus including means for separating from the vapour mixture of an emptied cylinder, a reusable halogenated hydrocarbon fluid for use by the cylinder filling apparatus.

Halogenated hydrocarbon recycling machine

Growing community of inventors

Dublin, Ireland

Brian Keogh